ReviewMayo Clinic proceedings2010
Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence.
Review in Mayo Clinic proceedings, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 125 citations in OpenAlex.
- A nested case-control study of monoclonal gammopathy of undetermined significance in the Multiethnic Cohort study.Blood advances · 2026Article
- Gammopathic optic neuritis: a case evolving from visual symptoms to MGUS diagnosis.Acta neurologica Belgica · 2026Article
- Machine Learning Model Predicts Monoclonal Gammopathy Using Routine Laboratory Values.JCO clinical cancer informatics · 2026Article
- Revised criteria for light chain MGUS enhance diagnostic accuracy and risk stratification.Blood cancer journal · 2026Article
- Case Report: longitudinal immunoglobulin abnormalities preceding IgA-λ MGUS and colonic DLBCL: a case suggesting immune-driven B-cell dysregulation.Frontiers in oncology · 2026Article
- NT-proBNP as a Biomarker in MGUS and Multiple Myeloma: A Retrospective Analysis.Journal of clinical medicine · 2025Article
- Assessing the performance of the Iceland screens, treats, or prevents multiple myeloma (iStopMM) model in a multicultural Bronx cohort: implications for monoclonal gammopathy of undetermined significance risk stratification.Blood cancer journal · 2025Article
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma.Cancer biomarkers : section A of Disease markers · 2025Article
- Revised free light chain reference intervals enhance risk stratification in monoclonal gammopathy of undetermined significance and reduce overdiagnosis.Blood cancer journal · 2025Article
- Asymptomatic Incidence of Monoclonal Gammopathy of Undetermined Significance and Preclinical Duration to Myeloma Diagnosis: A Modeling Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Proteomic Alteration in the Progression of Multiple Myeloma: A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2023Review
- Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease.Nature communications · 2022Article
- Predictive Immune Markers for Disease Progression in Multiple Myeloma and Monoclonal Gammopathy of Undetermined SignificanceTurkish journal of haematology : official journal of Turkish Society of Haematology · 2022Article
- An Analysis of M-protein in Plasma cell Dyscrasia Patients Identifies that IgG Lambda Subtype is More Commonly Associated with Normal Serum Free Light Chain (SFLC) Ratio.Indian journal of clinical biochemistry : IJCB · 2022Article
- Monoclonal gammopathy of undetermined significance: evaluation, risk assessment, management, and beyond.Faculty reviews · 2022Review
- A case of monoclonal gammopathy of undetermined significance and minimal change disease complicated by bilateral pulmonary emboli.SAGE open medical case reports · 2022Article
- Article
- Proliferation to Apoptosis Tumor Cell Ratio as a Biomarker to Improve Clinical Management of Pre-Malignant and Symptomatic Plasma Cell Neoplasms.International journal of molecular sciences · 2021Article
- Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment.American journal of cancer research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.